Method for the diagnosis of neuromyelitis optica
The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.
1. An autoantigen consisting of the amino acid sequence of SEQ ID NO: 2.
2. Autoantigens for in vitro diagnosis of neuromyelitis optica consisting of an amino acid sequence, which contain the following sequences selected from the group SDRPTARRWGKCGP (SEQ ID NO: 3), GGTEKPLPVD (SEQ ID NO: 4), CDSKRTD (SEQ ID NO: 5), NPARSFG (SEQ ID NO: 6), EFKRRFKEAFSKAA (SEQ ID NO: 7) or EFKRRFKEAFSKAAQQ (SEQ ID NO: 8) or EFKRRFKEAFSKAAQQTKG (SEQ ID NO: 9), DVDRGEEKKGKDQSGE (SEQ ID NO: 10) and comprise at least one spacer which contains 2 to 30 amino acids, 2 to 20 amino acids, or 2 to 10 amino acids, and the polypeptide that is obtained consists of at most 250 amino acids, wherein the spacer does not contain any amino acid sequence of SEQ ID NO: 1.
3. A kit for in vitro diagnosis of neuromyelitis optica, containing artificial aquaporin-4 peptides, detection reagents and auxiliary agents, wherein said artificial aquaporin-4 peptides contain the following sequences selected from the group SDRPTARRWGKCGP (SEQ ID NO: 3), GGTEKPLPVD (SEQ ID NO: 4), CDSKRTD (SEQ ID NO: 5), NPARSFG (SEQ ID NO: 6), EFKRRFKEAFSKAA (SEQ ID NO: 7) or EFKRRFKEAFSKAAQQ (SEQ ID NO: 8) or EFKRRFKEAFSKAAQQTKG (SEQ ID NO: 9), DVDRGEEKKGKDQSGE (SEQ ID NO: 10) and comprise at least one spacer which contains 2 to 30 amino acids, 2 to 20 amino acids, or 2 to 10 amino acids, and the polypeptide that is obtained consists of at most 250 amino acids, wherein the spacer does not contain any amino acid sequence of SEQ ID NO: 1, or the amino acid sequence of SEQ ID NO: 2.